Introduction
and no data are available on involvement of CTGF in modulation of inflammation or immune reactions. Connective tissue growth factor (CTGF ) is a novel growth factor, that occurs in a broad range of species, including man, pig, rat, mouse, cow, newt and frog.
Its amino acid sequence is over 90% identical among CTGF-expression in renal disease mammals. In their quest for the genes involved in development of atherosclerosis and diabetic nephro-Fibrosis is a final common pathway of renal diseases pathy, differential cloning strategies applied by Oemar of diverse aetiology, including inflammatory, haemoet al. [1] , Mason et al. [2] and Murphy et al. [3] dynamic, and metabolic injury. To answer the question independently revealed strong overexpression of this in which of these conditions CTGF expression might growth factor in atherosclerotic aorta, and in mesangial be altered, Ito et al. [5] performed CTGF mRNA cells after prolonged culture in high concentrations of in-situ hybridization (ISH ) and morphometry in 65 glucose, respectively. Previously, CTGF had been human renal biopsies. In control human kidney, CTGF cloned from HUVEC by Bradham et al. Its mouse mRNA was mainly expressed in visceral epithelial cells, ortholog (fisp-12) had been identified in serum-parietal epithelial cells, and some interstitial cells. stimulated NIH3T3 cells in 1988 by Almendra et al. CTGF mRNA was strongly upregulated in extracapil-(reviewed in [4] ).
lary and severe mesangial proliferative lesions of crescentic glomerulonephritis, IgA nephropathy, focal and segmental glomerulosclerosis and, notably, diabetic
Growth factors in renal fibrosis
nephropathy. In contrast, CTGF expression appeared not to be increased in glomerular diseases characterized With respect to the kidney, CTGF represents the latest by non-inflammatory lesions and proteinuria, such as addition to the list of growth factors that might be minimal change nephrotic syndrome and membranous involved in renal fibrosis. Does the present knowledge nephropathy, nor in acute exsudative postinfectious justify further analysis of its biological significance by glomerulonephritis, which tend to heal without excessresearchers in nephrology?
ive scarring. The number of cells expressing CTGF Among previously identified growth factors, TGFb mRNA was strongly correlated with the degree of is generally considered to be of major importance in injury at sites of chronic tubulointerstitial damage. the development of fibrosis. Blocking TGFb with neut-Unlike PDGF and TGFb, CTGF appeared to be ralizing antibody or decorin proved effective in redu-expressed only in resident cells of the kidney; doublecing glomerulosclerosis in experimental models. staining for CD68 excluded co-expression of CTGF in However, it is well known that TGFb also has antipro-monocytes or macrophages. The mRNA data were liferative (tumour suppressor) and anti-inflammatory later confirmed at the protein level by immunohistoactivities. A possible danger of blocking TGFb activity chemistry [6 ] ( Figure 1) . is exemplified by the hyperinflammatory ( lethal ) These (ISH ) observations were the first indication phenotype of TGFb knock-out mice. Therefore, identi-that CTGF overexpression might be involved in renal fication of more specific targets for antifibrotic therapy fibrosis, a notion further substantiated in the subis needed.
sequent study of two rat models of renal wound repair CTGF might well be such a target, as it seems to be and scarring, one initiated by acute, transient inflaman important downstream mediator of at least part of mation (anti-Thy1 nephritis), the other by chronic the pro-fibrotic activity of TGFb. However, it lacks, hypertension (in uninephrectomized spontaneously for example, the anti-proliferative effect of TGFb on hypertensive rats). In anti-Thy1 nephritis, CTGF mink lung epithelial cells. CTGF expression has thus mRNA was already upregulated in mesangial cells and podocytes before glomerular expression of aSMA did appear. Glomerular expression of CTGF mRNA
Correspondence and offprint requests to: R. Goldschmeding, Dept peaked at day 7, when damage was maximal, and of Pathology H04.312, Academic Hospital Utrecht, PO BOX 85500, returned to near-background levels at day 14 when hypertension model, significant upregulation of CTGF at positions −157 to −145 of the CTGF promoter sequence (reviewed in [4] ). mRNA was observed in damaged glomeruli undergoing sclerosis and in fibrotic interstitium. Moreover, Coordinate expression of TGFb 2 protein and CTGF mRNA in anti-Thy1 nephritis suggested that, at least also epithelial cells lining atrophic tubuli expressed CTGF mRNA [8] . Stenson et al. [9] and Taal et al. in this model, increased TGFb 2 might have induced the upregulation of CTGF mRNA [7] . Dammeier [10] reported upregulation of CTGF in 5/6 nephrectomy, which was attenuated by the ACE inhibitor et al. observed that systemic dexamethasone treatment increased CTGF mRNA in kidney, heart, and skin. It enalapril.
Another important in-vivo observation was made is of interest that dexamethasone treatment of NIH3T3 cells increased CTGF mRNA, but downregulated by Riser et al. [11] who, in agreement with Ito's ISH results in human renal biopsies, measured a two-fold TGFb mRNA (reviewed in [4] ). Because of the extensive use of steroids in the treatment of renal diseases, it increase of CTGF transcripts in renal cortex, and even a 42-fold increase in microdissected glomeruli of obese will be important to establish the net effect of their apparently opposite action on CTGF and TGFb db/db rats suffering from diabetic glomerulopathy. Makino et al. [12] reported less impressive (i.e. 1.7-expression. fold ) upregulation of CTGF mRNA in glomeruli of
In vitro, Ito et al. [7] have observed that TGFb1, 2 Wistar rats 4 weeks after treatment with STZ. and 3, but not PDGF, stimulate CTGF expression in Thus, results obtained from both human biopsies serum-starved mesangial cells and glomerular visceral and experimental models indicate that upregulation of epithelial cells. Riser et al. [14] , Murphy et al. [3] and CTGF in damaged glomeruli and (tubulo-) interstitial (earlier) Mason and co-workers [2], have independareas is a common phenomenon in diseases that lead ently detected upregulation of CTGF transcripts in to renal scarring. Moreover, the kinetics and topo-mesangial cells upon prolonged culture in high-glucose graphy of its expression following renal damage, sug-medium. This upregulation could be partially blocked gest that prolonged overexpression of CTGF might be by anti-TGFb1 antibody and by inhibition of protein actively involved in glomerular and tubulointerstitial kinase C activity. Riser et al. [14] reported blocking scarring.
of high glucose induction of CTGF by TGFb-neutralizing antibody. CTGF was also upregulated in renal epithelial monolayers after scrape-wounding or after
Regulation of (renal ) CTGF expression
exposure to calcium-oxalate-monohydrate crystals [5, 6 ] . Again, this may have been due to the increased level of TGFb detected under both conditions. TNFa, cAMP and recently NO [13] have been It thus appears that TGFb can be a major stimulator observed to suppress CTGF mRNA transcription.
of CTGF upregulation in renal fibrosis, but a role for TGFb thus far seems to be the most important inducer other factors has not been excluded. Recent reports of CTGF mRNA, which involves protein kinase A activity and a unique TGFb response element located suggest a possible role for HGF, IL-1b, IL-4, TNF-a and cyclic mechanical strain [9, 10, 14, 17] 
binding and CTGF-induced migration of endothelial that it would increase fibrosis, and whether blocking CTGF would significantly inhibit the profibrotic action cells. Binding studies with labelled CTGF have demonstrated specific high-and low-affinity binding sites on of TGFb in the kidney.
fibroblasts and chondrocytes. Co-precipitation revealed a 280 kDa cross-linked CTGF complex, but
Biological effects of CTGF
evidence for a signal transducing receptor is still lacking (reviewed in [4] ). In-vivo data on biological effects of CTGF in renal tissue are not available. Outside the kidney, CTGF induced angiogenesis in corneal micropocket implants CTGF levels in blood and body fluids and chorioallantoic membrane, and granulation tissue formation and fibrosis upon subcutaneous injection Finally, soluble CTGF, and 10-24 kDa isoforms [18, 19] and (reviewed in [4] ).
thereof, have been detected in serum, in uterine luminal With respect to renal fibrosis, important processes flushings, and in follicular, amniotic, peritoneal and in which CTGF might be involved include interstitial, cerebrospinal fluids. In biliary atresia, serum levels extracapillary, and mesangial accumulation of cells were up to 8-fold higher than those in controls and extracellular matrix, and vascular sclerosis. In the (reviewed in [4] ). Although serum and urine levels accumulation of cells, the following have been implic-have not yet been investigated in renal disease, it is ated: proliferation and migration of mesangial cells, challenging to speculate about the potential value of (cortical interstitial ) fibroblasts, possibly circulating such measurements for diagnosis or prognosis. fibroblast progenitor cells, and trans-differentiation of mesangial cells and tubular epithelial cells to obtain a myofibroblastic phenotype. Indeed, Blom et al. [20] Conclusion observed that CTGF, like TGFb, improved woundhealing of scraped mesangial cell monolayers, but that CTGF can be considered an interesting target for the response to CTGF was not affected by anti-TGFb future antifibrotic strategies. Its angiogenic potency antibody, and vice versa. Neither CTGF, nor TGFb and possible involvement in development of atheroinduced proliferation of mesangial cells. Moreover, sclerosis extend the potential importance of CTGF in CTGF increased fibronectin (FN ) expression in cul-nephrology to renal arteriosclerosis, chronic transplant tured mesangial cells (as was also observed by Murphy nephropathy, shunt-vasculopathy and possibly CAPDet al. upregulation in anti-Thy1 nephritis suggest that These data suggest that CTGF can contribute to properly controlled expression of CTGF might be increased mesangial cellularity (by stimulating migra-beneficial in tissue repair and adaptation to stress. An tion, and possibly hypertrophy) and synthesis of extra-important goal for the near future is to identify the cellular matrix, but also that CTGF seems not to be receptor(s) that mediate CTGF effects, and to establish directly involved in the acquisition of the myofibroblast whether modification of CTGF activity in vivo affects phenotype. Also, proliferation of mesangial cells was the natural course of tissue repair and/or the developnot altered by CTGF or CTGF neutralizing antibody. ment of fibrotic scarring after renal injury. Possible effects on matrix-modulating protease and protease-inhibitor activity, and on other renal cell
